OncoMatch/Clinical Trials/NCT06783829
A Study of SHR-4394 Injection in Subjects With Prostate Cancer
Is NCT06783829 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies SHR4394 for prostate cancer.
Treatment: SHR4394 — This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: luteinizing hormone releasing hormone analogue or bilateral orchidectomy
Continuous treatment with luteinizing hormone releasing hormone analogues (LHRHa) or previous bilateral orchidectomy
Cannot have received: systemic anticancer treatments or clinical investigational drugs
Exception: within 4 weeks prior to the initiation of the study treatment
Received systemic anticancer treatments or clinical investigational drugs 4 weeks prior to the initiation of the study treatment
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06783829 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer treatments or clinical investigational drugs disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 85 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages